MAGEA4 and synovial sarcoma: Eligible adult patients for this therapy must have unresectable or metastatic SS who have received prior chemotherapy, are HLA antigen A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06p-positive, and whose tumor expresses MAGE-A4 antigen [21, 22].